Catecholamin能多态性心动过速(CPVT)中SGT-501基因治疗的研究 (ARTEMIS)
一项1B期,多中心,开放标签的剂量发现研究,以研究单次静脉剂量的SGT-501对儿茶酚胺能多态性心动过速的患者的安全性和耐受性
This is a Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in participants with catecholaminergic polymorphic ventricular tachycardia (CPVT). The first-in-human (FIH) safety study will focus on obtaining safety data in adult participants. Cohort 1 and Cohort 2 (optional for dose exploration) will include participants ≥ 18 years of age. Cohort 3 will include participants ≥ 7 to < 18 years of age and will be initiated following data and safety monitoring board (DSMB) recommendations. Participants will be monitored for 5 years post-administration of SGT-501 including the active treatment period (1 year) and long-term follow-up (LTFU) (4 years) period.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Solid Bio Clinical Trials
- 电话号码:617-337-4680
- 邮箱:clinicaltrials@solidbio.com
学习地点
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、BC V6Z 1Y6
- 招聘中
- St. Paul's Hospital
-
接触:
- Brianna Davies
- 电话号码:64252 604-682-2344
- 邮箱:brianna.davies@phc.ca
-
首席研究员:
- Thomas Roston, MD
-
-
-
-
Massachusetts
-
Boston、Massachusetts、美国、02459
- 招聘中
- Boston Children's Hospital
-
接触:
- Elizabeth DeWitt, MD
- 邮箱:gene.therapy@childrens.harvard.edu
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- 招聘中
- Mayo Clinic
-
首席研究员:
- John Giudicessi, MD
-
接触:
- Sierra Slade
- 电话号码:507-422-5433
- 邮箱:Slade.Sierra@mayo.edu
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- 招聘中
- Cleveland Clinic
-
首席研究员:
- Peter Aziz, MD
-
接触:
- Paige Ewing
- 电话号码:216-445-8798
- 邮箱:ewingp@ccf.org
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- 尚未招聘
- University of Pennsylvania
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Type of Participant and Disease Characteristics:
- Clinical diagnosis of CPVT, based on documented history of polymorphic or bidirectional non-sustained ventricular tachycardia with exercise or ventricular ectopy in a pattern consistent with CPVT on EST.
- Central Screening laboratory determination of a RYR2 variant that is pathogenic or likely pathogenic for CPVT.
- Documented history of life-threatening ventricular arrhythmic event defined as: survived sudden cardiac arrest, sudden cardiac arrest with appropriate implantable cardioverter defibrillator (ICD) shock, arrhythmic syncope, or sustained ventricular tachycardia (30 seconds or more) with or without ICD shock.
- On stable dose (defined as no change in dose by more than 50% for at least 1 month prior to Screening) of standard-of-care therapy defined as a beta-blocker and/or flecainide.
- Documented prior history of EST demonstrating a ventricular arrythmia score (VAS) score of ≥ 2.
- For the first 2 participants in each cohort only: a properly functioning ICD device in place. Following review of data from Cohorts 1 and 2, the Data Safety and Monitoring Board (DSMB) will determine if this criterion is required for participants in Cohort 3.
- Must be up to date with meningococcal vaccination per national guidelines or willing to receive meningococcal vaccine to achieve this.
- Other inclusion criteria to be applied as per protocol.
Exclusion Criteria:
- Abnormal liver function: gamma-glutamyl transferase (GGT) > 1.5 × upper limit of normal [ULN] or total bilirubin > ULN).
- Abnormal renal function defined by estimated glomerular filtration rate < 60 milliliter /minute (mL/min)/1.73-square meter (m^2) using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula.
- Clinically significant abnormalities of coagulation including international normalized ratio or activated partial thromboplastin time > 1.2 × ULN or platelets < 150,000 cells/cubic millimeter (mm^3).
- Potential concomitant cardiomyopathy or inherited arrhythmia as evidenced by pathogenic or likely pathogenic mutation other than RYR2 obtained on cardiac panel during Screening.
- Current or prior treatment with an approved or investigational gene transfer drug.
- Exposure to another investigational drug within 90 days prior to Screening or 5 half-lives since last administration, whichever is longer.
- Contraindication or unwillingness to receive required immunosuppression regimen.
- Body mass index ≥ 30 kilograms per square meter (kg/m^2).
- Other exclusion criteria to be applied as per protocol.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Cohort 1 (≥ 18 years of age)
Participants will receive a single intravenous (IV) infusion (dose 1) of SGT-501. |
IV for infusion |
|
实验性的:Cohort 2 (≥ 18 years of age)
Participants will receive a single IV infusion (dose 2) of SGT-501. |
IV for infusion |
|
实验性的:Cohort 3 (≥ 7 to < 18 years)
Participants will receive a single IV infusion (level at or below dose(s) assessed in adults) of SGT-501. |
IV for infusion |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
第360天,患有治疗效果不良事件(TEAES)的参与者人数
大体时间:第360天首次剂量
|
第360天首次剂量
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in ventricular arrhythmia score (VAS) on exercise stress test (EST) at Day 180
大体时间:Baseline, Day 180
|
An EST will be used to evaluate ventricular arrhythmia scores. The EST will be performed using the standard Bruce treadmill protocol. |
Baseline, Day 180
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- SGT-501-101
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.